7 results on '"Ara, Takahide"'
Search Results
2. Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy.
- Author
-
Watanabe, Mizuki, Kanda, Junya, Fukuda, Takahiro, Uchida, Naoyuki, Ikegame, Kazuhiro, Kataoka, Keisuke, Kobayashi, Hikaru, Ara, Takahide, Ishikawa, Jun, Matsuoka, Ken‐ichi, Sugio, Yasuhiro, Nakazawa, Hideyuki, Ikeda, Takashi, Atsuta, Yoshiko, Kondo, Eisei, and Suzuki, Ritsuro more...
- Subjects
CELLULAR therapy ,LYMPHOMAS ,JAPANESE people ,PROGRESSION-free survival ,STEM cell transplantation - Abstract
Summary: The graft‐versus‐lymphoma (GVL) effect and its association with acute and chronic GVHD (aGVHD, cGVHD) has not been comprehensively elucidated. We retrospectively analysed 2204 Japanese patients with non‐Hodgkin lymphomas (NHLs; indolent B‐NHLs, n = 689; aggressive B‐NHLs, n = 720; mature T/NK‐NHLs, n = 795) receiving a first allo‐HSCT in 2003–2017. Pre‐transplant lymphoma control showed complete response (CR) in 759 and non‐CR in 1445. We assessed the impact of aGVHD/cGVHD on lymphoma progression and other outcomes. Although aGVHD/cGVHD showed no statistical impact on lymphoma progression in the overall cohort, their impact was clear in certain groups: Grade I‐II aGVHD in CR patients (HR, 0.63; 95% CI, 0.43–0.91), especially in mature T/NK‐NHL (HR, 0.46; 95% CI, 0.26–0.83) and extensive cGVHD in patients with mature aggressive B‐NHLs (HR, 0.55; 95% CI, 0.31–0.97). In total, limited cGVHD was associated with superior survivals (progression‐free survival: HR, 0.71; 95% CI, 0.56–0.90), whereas severe GVHDs showed negative impacts on them. Our results support the presence of GVL effects differentially associated with GVHD in different lymphoma subtypes/controls. Meanwhile, it was also suggested that we should manage GVHDs within a limited activity, considering the negative impact of severe GVHDs. As pre‐transplant lymphoma control remains a strong factor influencing transplant outcomes, improving its management is an important issue to be addressed. [ABSTRACT FROM AUTHOR] more...
- Published
- 2023
- Full Text
- View/download PDF
Catalog
3. Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working group.
- Author
-
Yanagisawa, Ryu, Tamaki, Masaharu, Tanoshima, Reo, Misaki, Yukiko, Uchida, Naoyuki, Koi, Satoshi, Tanaka, Takashi, Ozawa, Yukiyasu, Matsuo, Yayoi, Tanaka, Masatsugu, Ikegame, Kazuhiro, Katayama, Yuta, Matsuoka, Ken‐ichi, Ara, Takahide, Kanda, Yoshinobu, Matsumoto, Kimikazu, Fukuda, Takahiro, Atsuta, Yoshiko, Kato, Motohiro, and Nakasone, Hideki more...
- Subjects
CELLULAR therapy ,DISEASE risk factors ,HEMATOPOIETIC stem cell transplantation ,THERAPEUTIC complications ,CARDIOVASCULAR disease related mortality ,STEM cell transplantation ,MEDICAL records - Abstract
Fatal cardiac complications can occur from the early to late phases after hematopoietic cell transplantation (HCT). Herein, the Japanese transplant registry database was used to retrospectively analyze health records of 33,791 allogeneic HCT recipients to elucidate the pathogenesis and risk factors involved. Overall, 527 patients died of cardiac complications at a median of 130 (range 0–3924) days after HCT. The cumulative incidence of fatal cardiac complications was 1.2% (95% confidence interval [CI]: 1.0–1.3) and 1.6% (95% CI: 1.5–1.8) at 1 and 5 years after HCT, respectively. Fatal cardiovascular events were significantly associated with an HCT‐specific comorbidity index (HCT‐CI) score of ≥1 specific to the three cardiovascular items, lower performance status, conditioning regimen cyclophosphamide dose of >120 mg/kg, and female sex. Cardiovascular death risk within 60 days after HCT was associated with the type of conditioning regimen, presence of bacterial or fungal infections at HCT, and number of blood transfusions. Contrastingly, late cardiovascular death beyond 1 year after HCT was associated with female sex and older age. Lower performance status and positive cardiovascular disease‐related HCT‐CI were risk factors for cardiac complications in all phases after HCT. Systematic follow‐up may be necessary according to the patients' risk factors and conditions. [ABSTRACT FROM AUTHOR] more...
- Published
- 2023
- Full Text
- View/download PDF
4. Prognostic impact of complex and/or monosomal karyotypes in post‐transplant poor cytogenetic acute myeloid leukaemia: A quantitative approach.
- Author
-
Jo, Tomoyasu, Arai, Yasuyuki, Oshima, Shinichiro, Kondo, Tadakazu, Harada, Kaito, Uchida, Naoyuki, Doki, Noriko, Fukuda, Takahiro, Tanaka, Masatsugu, Ozawa, Yukiyasu, Kuriyama, Takuro, Ikegame, Kazuhiro, Katayama, Yuta, Ota, Shuichi, Ara, Takahide, Kawakita, Toshiro, Onizuka, Makoto, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Yanada, Masamitsu more...
- Subjects
ACUTE myeloid leukemia ,STEM cell transplantation ,KARYOTYPES ,STEM cell factor ,DISEASE risk factors ,HEMATOPOIETIC stem cell transplantation - Abstract
Summary: To evaluate the prognostic impact of complex karyotype (CK) and/or monosomal karyotype (MK) in combination with various clinical factors on allogeneic stem cell transplantation (HSCT) outcomes of patients with acute myeloid leukaemia (AML), we analysed the registry database of adult AML patients who underwent allogeneic HSCT between 2000 and 2019 in Japan. Among 16 094 patients, those with poor cytogenetic risk (N = 3345) showed poor overall survival (OS) after HSCT (25.3% at 5 years). Multivariate analyses revealed that CK and/or MK (hazard ratio [HR], 1.31 for CK without MK; 1.27 for MK without CK; and 1.73 for both), age at HSCT ≥50 years (HR, 1.58), male sex (HR, 1.40), performance status ≥2 (HR, 1.89), HCT‐CI score ≥3 (HR, 1.23), non‐remission status at HSCT (HR, 2.49), and time from diagnosis to HSCT ≥3 months (HR, 1.24) independently reduced post‐HSCT OS among patients with poor cytogenetic risk AML. A risk scoring system based on the multivariate analysis successfully stratified patients into five distinct groups for OS. This study confirms the negative effects of CK and MK on post‐HSCT outcomes, and offers a powerful risk scoring system for predicting prognoses after HSCT among AML patients with unfavourable cytogenetics. [ABSTRACT FROM AUTHOR] more...
- Published
- 2023
- Full Text
- View/download PDF
5. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.
- Author
-
Shimazu, Yutaka, Murata, Makoto, Kondo, Takeshi, Minami, Yosuke, Tachibana, Takayoshi, Doki, Noriko, Uchida, Naoyuki, Ozawa, Yukiyasu, Yano, Shingo, Fukuda, Takahiro, Kato, Jun, Ara, Takahide, Eto, Testuya, Ishikawa, Jun, Nakamae, Hirohisa, Tanaka, Junji, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Nagamura‐Inoue, Tokiko more...
- Subjects
CHRONIC myeloid leukemia ,STEM cell transplantation ,PROTEIN-tyrosine kinase inhibitors ,NILOTINIB ,DASATINIB ,CHRONIC leukemia ,OVERALL survival ,DATABASE management - Abstract
The introduction of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) treatment has dramatically improved the prognosis of CML patients and reduced the number of patients receiving allogeneic stem cell transplantation (allo‐SCT). However, the impact of the newest‐generation TKIs on the overall survival (OS) after allo‐SCT has not been well described. To investigate the beneficial effects of TKIs on the prognosis after allo‐SCT, we conducted a retrospective observational study using the Transplant Registry Unified Management Program database in Japan. We analyzed 1188 patients (male/female: 738/450; median age: 44 years; range: 16–75) who underwent their first allo‐SCT between January 2001 and December 2018. We divided the patients into two groups according to the TKI treatment used before allo‐SCT: group 1 was treated with the first generation TKI imatinib; group 2 was treated with the second generation TKIs nilotinib, dasatinib, or bosutinib and/or the third generation TKI ponatinib. We compared the post allo‐SCT OS between the two groups. The 3‐year OS rates (95%CI) of groups 1 and 2 were 59.3% (54.8%–63.5%) and 65.8% (61.6%–69.6%), respectively (p = 0.017). Multivariate analysis confirmed that group 2 had superior OS after allo‐SCT compared to group 1 (p = 0.002). Other factors associated with superior prognosis were age ≤65, performance status (PS) 0/1, a 6/6 HLA‐matched donor and chronic‐phase (CP) disease status at allo‐SCT. A subgroup analysis showed poor prognoses for patients who could not obtain a molecular response before allo‐SCT and patients with positive T315I mutation in the BCR/ABL gene. In group 2, early allo‐SCT was correlated with superior OS in patients with a blast‐crisis disease status at allo‐SCT (p = 0.001). The cumulative incidence of non‐relapse mortality rate significantly decreased in group 2 (p = 0.0005). The post allo‐SCT OS was improved both by pre‐ and post‐management of allo‐SCT and by the introduction of newer TKIs. [ABSTRACT FROM AUTHOR] more...
- Published
- 2022
- Full Text
- View/download PDF
6. High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease.
- Author
-
Shiratori, Souichi, Ohigashi, Hiroyuki, Ara, Takahide, Yasumoto, Atsushi, Goto, Hideki, Nakagawa, Masao, Sugita, Junichi, Onozawa, Masahiro, Kahata, Kaoru, Endo, Tomoyuki, Hashimoto, Daigo, and Teshima, Takanori more...
- Subjects
GRAFT versus host disease ,LYMPHOCYTE count ,ACUTE diseases ,STEM cell transplantation ,GLOBULINS ,AUTOIMMUNE hemolytic anemia - Abstract
Antithymocyte globulin (ATG) reduces severe acute and chronic graft-versus-host disease (GVHD) in allogeneic peripheral blood stem cell transplantation (PBSCT). However, risk factors for severe acute GVHD in PBSCT using ATG remain to be determined. We conducted a single-center, retrospective study to analyze the association of acute GVHD requiring systemic corticosteroid (SC-aGVHD) with absolute lymphocyte counts (ALC) before the administration of ATG or conditioning in 53 patients with HLA-matched PBSCT using low-dose thymoglobulin (2 mg/kg) after myeloablative conditioning. The cumulative incidence of SC-aGVHD was 17.0% and ALC before ATG were significantly higher in patients with SC-aGVHD compared to that in patients without it (median, 0.15 × 10
9 /L vs 0.06 × 109 /L, P = 0.047). The cumulative incidence of SC-aGVHD was significantly higher in patients with high ALC before ATG (≥ 0.15 × 109 /L) than in those with low ALC (38.5% vs 10.0%, P = 0.016). Non-relapse mortality (NRM) was also significantly higher in the high ALC before ATG group than the low ALC before ATG group (2-year NRM: 23.9% vs 6.0%, P = 0.048), leading to worse survival (2-year overall survival: 69.2% vs 83.5%, P = 0.039). Our study suggested that high ALC before ATG is a risk factor for SC-aGVHD. [ABSTRACT FROM AUTHOR] more...- Published
- 2021
- Full Text
- View/download PDF
7. Intestinal goblet cells protect against GVHD after allogeneic stem cell transplantation via Lypd8.
- Author
-
Ara, Takahide, Hashimoto, Daigo, Hayase, Eiko, Noizat, Clara, Kikuchi, Ryo, Hasegawa, Yuta, Matsuda, Kana, Ono, Shoko, Matsuno, Yoshihiro, Ebata, Ko, Ogasawara, Reiki, Takahashi, Shuichiro, Ohigashi, Hiroyuki, Yokoyama, Emi, Matsuo, Keitaro, Sugita, Junichi, Onozawa, Masahiro, Okumura, Ryu, Takeda, Kiyoshi, and Teshima, Takanori more...
- Subjects
STEM cell transplantation ,ALEMTUZUMAB ,COLON (Anatomy) ,HEMATOPOIETIC stem cell transplantation ,HEMATOPOIETIC stem cells ,CELL preservation ,MOTILITY of bacteria ,DIVERTICULOSIS - Abstract
Guarding the gut against GVHD: The gastrointestinal tract is one of the major target organs of graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplant. Goblet cells, mucus-secreting epithelial cells, are diminished in GVHD, but the pathophysiological implications were unknown. Ara et al. used mouse GVHD models to demonstrate that goblet cell loss disrupted the inner mucus layer of the colon and permitted bacterial translocation. GVHD was also exacerbated in mice lacking the antimicrobial Lypd8. Goblet cell preservation with IL-25 pretreatment maintained the gut barrier and blunted GVHD. In patient biopsies, goblet cell loss was associated with severe gastrointestinal GVHD and poor outcomes. Collectively, these results suggest that retaining goblet cells with IL-25 conditioning could prevent GVHD in the gut. Graft-versus-host disease (GVHD) and infection are major obstacles to successful allogeneic hematopoietic stem cell transplantation (HSCT). Intestinal goblet cells form the mucus layers, which spatially segregate gut microbiota from host tissues. Although it is well known that goblet cell loss is one of the histologic features of GVHD, effects of their loss in pathophysiology of GVHD remain to be elucidated. In mouse models of allogeneic HSCT, goblet cells in the colon were significantly reduced, resulting in disruption of the inner mucus layer of the colon and increased bacterial translocation into colonic mucosa. Pretransplant administration of interleukin-25 (IL-25), a growth factor for goblet cells, protected goblet cells against GVHD, prevented bacterial translocation, reduced plasma concentrations of interferon-γ (IFN-γ) and IL-6, and ameliorated GVHD. The protective role of IL-25 was dependent on Lypd8, an antimicrobial molecule produced by enterocytes in the colon that suppresses motility of flagellated bacteria. In clinical colon biopsies, low numbers of goblet cells were significantly associated with severe intestinal GVHD, increased transplant-related mortality, and poor survival after HSCT. Goblet cell loss is associated with poor transplant outcome, and administration of IL-25 represents an adjunct therapeutic strategy for GVHD by protecting goblet cells. [ABSTRACT FROM AUTHOR] more...
- Published
- 2020
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.